



Clinical trial results:

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

Summary

EudraCT number	2013-003519-23
Trial protocol	HU CZ SK SE NL DE IT GB ES NO AT DK BE FI BG FR
Global end of trial date	16 February 2019

Results information

Result version number	v2 (current)
This version publication date	06 May 2020
First version publication date	26 January 2020
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	D513BC00001
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01991795
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	Pepparedsleden 1, Mölndal, Sweden, 43183
Public contact	Global Clinical Lead, Study Information center, +1 877 240 9479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, Study Information center, +1 877 240 9479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 February 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 February 2019
Global end of trial reached?	Yes
Global end of trial date	16 February 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to compare the effect of long-term treatment with ticagrelor twice daily (bd) vs. placebo for the prevention of major cardiovascular (CV) events (composite of CV death, myocardial infarction [MI] or stroke) in patients with Type 2 Diabetes Mellitus (T2DM) at high risk for CV events, but without a previous medical history of MI or stroke. The primary efficacy variable is time from randomisation to first occurrence of any event from the composite of CV death, MI or stroke (ischaemic, haemorrhagic or unknown etiology).

Protection of trial subjects:

Treated in routine care, on a background therapy of acetylsalicylic acid (ASA).

Background therapy:

Patients should be treated with low-dose acetylsalicylic acid (ASA) unless contraindicated or not tolerated, in accordance with national and international clinical practice guidelines.

Evidence for comparator: -

Actual start date of recruitment	10 February 2014
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	40 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 1636
Country: Number of subjects enrolled	Russian Federation: 1121
Country: Number of subjects enrolled	Argentina: 394
Country: Number of subjects enrolled	Australia: 188
Country: Number of subjects enrolled	Austria: 87
Country: Number of subjects enrolled	Belgium: 217
Country: Number of subjects enrolled	Bulgaria: 878
Country: Number of subjects enrolled	Brazil: 811
Country: Number of subjects enrolled	Canada: 729
Country: Number of subjects enrolled	Chile: 300
Country: Number of subjects enrolled	China: 910
Country: Number of subjects enrolled	Colombia: 136
Country: Number of subjects enrolled	Czech Republic: 602
Country: Number of subjects enrolled	Denmark: 243
Country: Number of subjects enrolled	Germany: 547

Country: Number of subjects enrolled	Spain: 340
Country: Number of subjects enrolled	Finland: 118
Country: Number of subjects enrolled	France: 172
Country: Number of subjects enrolled	United Kingdom: 246
Country: Number of subjects enrolled	Hong Kong: 152
Country: Number of subjects enrolled	Hungary: 616
Country: Number of subjects enrolled	India: 292
Country: Number of subjects enrolled	Israel: 117
Country: Number of subjects enrolled	Italy: 130
Country: Number of subjects enrolled	Japan: 496
Country: Number of subjects enrolled	Korea, Republic of: 870
Country: Number of subjects enrolled	Mexico: 364
Country: Number of subjects enrolled	Netherlands: 479
Country: Number of subjects enrolled	Norway: 191
Country: Number of subjects enrolled	Peru: 173
Country: Number of subjects enrolled	Philippines: 92
Country: Number of subjects enrolled	Romania: 80
Country: Number of subjects enrolled	Saudi Arabia: 155
Country: Number of subjects enrolled	Slovakia: 244
Country: Number of subjects enrolled	Thailand: 231
Country: Number of subjects enrolled	Turkey: 225
Country: Number of subjects enrolled	Sweden: 224
Country: Number of subjects enrolled	Taiwan: 803
Country: Number of subjects enrolled	Ukraine: 792
Country: Number of subjects enrolled	United States: 2266
Country: Number of subjects enrolled	Vietnam: 254
Country: Number of subjects enrolled	South Africa: 299
Worldwide total number of subjects	19220
EEA total number of subjects	7050

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	7934
From 65 to 84 years	11115
85 years and over	171

Subject disposition

Recruitment

Recruitment details:

In total, 20108 patients were enrolled, 19220 patients were randomised to study drug and included in the analyses, from 1315 study sites in 42 countries. The first patient was enrolled on 10 February 2014. The last patient visit took place on 25 January 2019.

Pre-assignment

Screening details:

Enrolled patients randomised to study drug 95.8%; n =19271, of which 51 patients were randomised to study drug at a site prematurely closed by sponsor and excluded from the study results. Patients who were not randomised 4.2%; n=837. Patient did not meet inclusion/exclusion criteria n=454, Patient decision n=256, Death n=1, Other reason n=131.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Ticagrelor 60 mg

Arm description:

Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.

Arm type	Experimental
Investigational medicinal product name	Ticagrelor 90mg film-coated tablets
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

90 mg twice daily

Investigational medicinal product name	Ticagrelor 60mg film-coated tablets
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

60 mg twice daily

Arm title	Ticagrelor placebo
------------------	--------------------

Arm description:

Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.

Arm type	Placebo
Investigational medicinal product name	Ticagrelor 60 mg placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Matching 60mg ticagrelor placebo twice daily

Investigational medicinal product name	Ticagrelor 90 mg placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Matching 90mg ticagrelor placebo twice daily

Number of subjects in period 1	Ticagrelor 60 mg	Ticagrelor placebo
Started	9619	9601
Completed	9496	9503
Not completed	123	98
Consent withdrawn by subject	117	94
Lost to follow-up	6	4

Baseline characteristics

Reporting groups

Reporting group title	Ticagrelor 60 mg
Reporting group description:	
Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.	
Reporting group title	Ticagrelor placebo
Reporting group description:	
Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.	

Reporting group values	Ticagrelor 60 mg	Ticagrelor placebo	Total
Number of subjects	9619	9601	19220
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3975	3959	7934
From 65-84 years	5560	5555	11115
85 years and over	84	87	171
Age Continuous			
Units: Years			
arithmetic mean	66.3	66.3	-
standard deviation	± 7.8	± 7.7	-
Sex: Female, Male			
Units: Subjects			
Male	6576	6613	13189
Female	3043	2988	6031
Region of Enrollment			
Units: Subjects			
ARG	195	199	394
AUS	94	94	188
AUT	42	45	87
BEL	109	108	217
BGR	435	443	878
BRA	412	399	811
CAN	364	365	729
CHL	152	148	300
CHN	456	454	910
COL	68	68	136
CZE	304	298	602
DEU	277	270	547
DNK	123	120	243

ESP	170	170	340
FIN	60	58	118
FRA	85	87	172
GBR	123	123	246
HKG	76	76	152
HUN	306	310	616
IND	147	145	292
ISR	60	57	117
ITA	67	63	130
JPN	246	250	496
KOR	433	437	870
MEX	182	182	364
NLD	242	237	479
NOR	95	96	191
PER	91	82	173
PHL	47	45	92
POL	815	821	1636
ROU	37	43	80
RUS	561	560	1121
SAU	79	76	155
SVK	122	122	244
SWE	110	114	224
THA	115	116	231
TUR	113	112	225
TWN	402	401	803
UKR	399	393	792
USA	1126	1140	2266
VNM	129	125	254
ZAF	150	149	299
Race/Ethnicity, Customized Units: Subjects			
White	6838	6858	13696
Black or african american	205	198	403
Asian	2211	2195	4406
Native hawaiian or other pacific islander	7	7	14
American indian or alaska native	161	152	313
Other	197	191	388

End points

End points reporting groups

Reporting group title	Ticagrelor 60 mg
Reporting group description: Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.	
Reporting group title	Ticagrelor placebo
Reporting group description: Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.	

Primary: Composite of Cardiovascular (CV) Death, MI or Stroke

End point title	Composite of Cardiovascular (CV) Death, MI or Stroke
End point description: Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date.	
End point type	Primary
End point timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9619	9601		
Units: Number of participants with event	736	818		

Statistical analyses

Statistical analysis title	Prevention of composite of CV death, MI or stroke
Statistical analysis description: Time to first occurrence of any event from the composite of CV death, MI or stroke.	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19220
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0378 ^[1]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	0.99

Notes:

[1] - The hypothesis will be tested at the 4.96% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing

Secondary: CV death

End point title	CV death
-----------------	----------

End point description:

Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9619	9601		
Units: Number of participants with event	364	357		

Statistical analyses

Statistical analysis title	Prevention of CV death
----------------------------	------------------------

Statistical analysis description:

Time from randomisation to death of CV cause

Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19220
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7883 ^[2]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.02

Confidence interval

level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.18

Notes:

[2] - The hypothesis will be tested at the 4.96% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing

Secondary: MI

End point title	MI
End point description: Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date	
End point type	Secondary
End point timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9619	9601		
Units: Number of participants with event	274	328		

Statistical analyses

Statistical analysis title	Prevention of MI
Statistical analysis description: Time from randomisation to first occurrence of MI.	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19220
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0294 ^[3]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	0.98

Notes:

[3] - The hypothesis will be tested at the 4.96% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing

Secondary: Ischaemic stroke

End point title	Ischaemic stroke
End point description: Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date.	
End point type	Secondary
End point timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9619	9601		
Units: Number of participants with event	152	191		

Statistical analyses

Statistical analysis title	Prevention of ischaemic stroke
Statistical analysis description:	
Time from randomisation to first occurrence of ischaemic stroke	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19220
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0375 ^[4]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	0.99

Notes:

[4] - The hypothesis will be tested at the 4.96% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing

Secondary: All-cause death

End point title	All-cause death
End point description:	
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent.	
End point type	Secondary
End point timeframe:	
From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9619	9601		
Units: Number of participants with event	579	592		

Statistical analyses

Statistical analysis title	Prevention of all-cause death
Statistical analysis description:	
Time from randomisation to death of any cause	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19220
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6846
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.1

Other pre-specified: TIMI Major bleeding event (primary safety objective)

End point title	TIMI Major bleeding event (primary safety objective)
End point description:	
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication	
End point type	Other pre-specified
End point timeframe:	
From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9562 ^[5]	9531 ^[6]		
Units: Number of participants with event	206	100		

Notes:

[5] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

[6] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

Statistical analyses

Statistical analysis title	TIMI major bleeding
Statistical analysis description:	
Time to first TIMI major bleeding event	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19093
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	2.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.82
upper limit	2.94

Other pre-specified: TIMI major or minor bleeding event

End point title	TIMI major or minor bleeding event
End point description:	
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication	
End point type	Other pre-specified
End point timeframe:	
From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.	

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9562 ^[7]	9531 ^[8]		
Units: Number of participants with event	285	129		

Notes:

[7] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

[8] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

Statistical analyses

Statistical analysis title	TIMI major or minor bleeding
Statistical analysis description:	
Time to first TIMI major or minor bleeding	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo

Number of subjects included in analysis	19093
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	2.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.02
upper limit	3.07

Other pre-specified: PLATO major bleeding event

End point title	PLATO major bleeding event
End point description:	Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication
End point type	Other pre-specified
End point timeframe:	From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9562 ^[9]	9531 ^[10]		
Units: Number of participants with event	310	145		

Notes:

[9] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

[10] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

Statistical analyses

Statistical analysis title	PLATO major bleeding
Statistical analysis description:	
Time to first PLATO major bleeding	
Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19093
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	2.41

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.98
upper limit	2.93

Other pre-specified: Permanent discontinuation of study medication due to any bleeding event

End point title	Permanent discontinuation of study medication due to any bleeding event
-----------------	---

End point description:

Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.

End point values	Ticagrelor 60 mg	Ticagrelor placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9562 ^[11]	9531 ^[12]		
Units: Number of participants with event	466	125		

Notes:

[11] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

[12] - Safety analyses included subjects who received at least 1 dose of randomised ticagrelor or placebo

Statistical analyses

Statistical analysis title	Permanent discontinuation of IP due to bleeding
----------------------------	---

Statistical analysis description:

Time to permanent discontinuation of study medication due to any bleeding event

Comparison groups	Ticagrelor 60 mg v Ticagrelor placebo
Number of subjects included in analysis	19093
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	4.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.32
upper limit	4.92

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Randomisation until last dose of study drug + 7 days

Adverse event reporting additional description:

Systematic assessment of suspected bleeding events, suspected endpoint events, serious adverse events, adverse events that leads to permanent discontinuation of study medication and non-serious AEs of interest (ie, dyspnoea, renal impairment, bradyarrhythmia, gout, and pneumonia),

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

Reporting groups

Reporting group title	Ticagrelor
-----------------------	------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Ticagrelor	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	3049 / 9562 (31.89%)	3210 / 9531 (33.68%)	
number of deaths (all causes)	187	223	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Abdominal neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Acute promyelocytic leukaemia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	14 / 9562 (0.15%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 14	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adrenal adenoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			

subjects affected / exposed	5 / 9562 (0.05%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	1 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastric neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign ovarian tumour			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bladder cancer			
subjects affected / exposed	8 / 9562 (0.08%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bladder cancer recurrent			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			

subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer metastatic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Brain neoplasm malignant			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast cancer			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer female			
subjects affected / exposed	9 / 9562 (0.09%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 3	0 / 0	
Breast cancer metastatic			

subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Carcinoid tumour			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellopontine angle tumour			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma recurrent			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cervix carcinoma stage 0			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Cholesteatoma			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chordoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myeloid leukaemia			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Clear cell renal cell carcinoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	12 / 9562 (0.13%)	16 / 9531 (0.17%)	
occurrences causally related to treatment / all	0 / 12	0 / 16	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon cancer metastatic			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Colon neoplasm			

subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	0 / 9562 (0.00%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cutaneous lymphoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer metastatic			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrosarcoma			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrous histiocytoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder adenoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cancer			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric adenoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	7 / 9562 (0.07%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	1 / 7	1 / 10	
deaths causally related to treatment / all	1 / 1	0 / 3	
Gastric neoplasm			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal lymphoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal melanoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal stromal tumour			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cancer			

subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Hepatic cancer metastatic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatobiliary neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatocellular carcinoma			
subjects affected / exposed	9 / 9562 (0.09%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 3	
Invasive breast carcinoma			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine benign neoplasm			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal neoplasm			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lentigo maligna			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukaemia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lip and/or oral cavity cancer			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip neoplasm malignant stage unspecified			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipofibroma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	3 / 9562 (0.03%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung cancer metastatic			

subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Lung neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	14 / 9562 (0.15%)	20 / 9531 (0.21%)	
occurrences causally related to treatment / all	0 / 14	1 / 20	
deaths causally related to treatment / all	0 / 8	0 / 12	
Lymphoma			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	7 / 9562 (0.07%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of renal pelvis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to liver			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to lung			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to pleura			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic gastric cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic malignant melanoma			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoclonal gammopathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Muscle neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nasopharyngeal cancer			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			

subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Neoplasm prostate			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal neoplasm			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral neoplasm benign			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			

subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Ovarian fibroma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian granulosa cell tumour			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasm			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	12 / 9562 (0.13%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	1 / 13	1 / 12	
deaths causally related to treatment / all	0 / 8	1 / 7	
Pancreatic carcinoma metastatic			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Pancreatic neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pancreatic neuroendocrine tumour			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic sarcoma			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Papillary cystadenoma lymphomatosum			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penis carcinoma metastatic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Phyllodes tumour			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			

subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasmacytoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleomorphic liposarcoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural neoplasm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Prostate cancer			
subjects affected / exposed	31 / 9562 (0.32%)	36 / 9531 (0.38%)	
occurrences causally related to treatment / all	0 / 31	0 / 36	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 3	
Prostate cancer recurrent			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Prostate cancer stage 0			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	9 / 9562 (0.09%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 9	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer recurrent			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer metastatic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	3 / 9562 (0.03%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 3	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cell carcinoma			
subjects affected / exposed	5 / 9562 (0.05%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal neoplasm			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland adenoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Small cell lung cancer recurrent			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine adenocarcinoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine carcinoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue sarcoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma of lung			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the cervix			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
subjects affected / exposed	0 / 9562 (0.00%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thyroid cancer recurrent			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell cancer of the renal pelvis and ureter			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	4 / 9562 (0.04%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma stage I			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage II			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer stage I			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer stage II			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant neoplasm papilla of Vater			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage III			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Air embolism			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiopathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			

subjects affected / exposed	8 / 9562 (0.08%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic arteriosclerosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	5 / 9562 (0.05%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial occlusive disease			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Artery dissection			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atherosclerotic plaque rupture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure inadequately controlled			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Deep vein thrombosis			
subjects affected / exposed	6 / 9562 (0.06%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism arterial			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism venous			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			

subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	36 / 9562 (0.38%)	45 / 9531 (0.47%)	
occurrences causally related to treatment / all	0 / 40	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	15 / 9562 (0.16%)	23 / 9531 (0.24%)	
occurrences causally related to treatment / all	0 / 17	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	9 / 9562 (0.09%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery disease			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery embolism			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			

subjects affected / exposed	9 / 9562 (0.09%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labile blood pressure			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocele			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrosis ischaemic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurogenic shock			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	7 / 9562 (0.07%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			

subjects affected / exposed	31 / 9562 (0.32%)	48 / 9531 (0.50%)	
occurrences causally related to treatment / all	0 / 38	0 / 60	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	10 / 9562 (0.10%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	5 / 9562 (0.05%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral coldness			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	14 / 9562 (0.15%)	18 / 9531 (0.19%)	
occurrences causally related to treatment / all	0 / 17	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			

subjects affected / exposed	3 / 9562 (0.03%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid vasculitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Shock haemorrhagic			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery stenosis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subgaleal haematoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular compression			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular occlusion			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Administration site phlebitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			

subjects affected / exposed	4 / 9562 (0.04%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Capsular contracture associated with breast implant			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac death			
subjects affected / exposed	4 / 9562 (0.04%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 4	0 / 1	
Catheter site haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	5 / 9562 (0.05%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	6 / 9562 (0.06%)	11 / 9531 (0.12%)	
occurrences causally related to treatment / all	1 / 6	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	52 / 9562 (0.54%)	60 / 9531 (0.63%)	
occurrences causally related to treatment / all	0 / 52	1 / 60	
deaths causally related to treatment / all	0 / 52	1 / 60	
Drowning			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Facial pain			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body reaction			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait inability			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site haemorrhage			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal exfoliation			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Necrobiosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrosis			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodule			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	54 / 9562 (0.56%)	66 / 9531 (0.69%)	
occurrences causally related to treatment / all	0 / 60	0 / 72	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			

subjects affected / exposed	1 / 9562 (0.01%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker generated arrhythmia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	8 / 9562 (0.08%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	6 / 9562 (0.06%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	1 / 6	0 / 8	
deaths causally related to treatment / all	1 / 6	0 / 8	
Sudden death			
subjects affected / exposed	5 / 9562 (0.05%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 5	0 / 5	
Ulcer haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	6 / 9562 (0.06%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to arthropod bite			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	0 / 9562 (0.00%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contrast media allergy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	0 / 9562 (0.00%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 0	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoidosis			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant rejection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Acquired hydrocele			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired phimosis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	26 / 9562 (0.27%)	21 / 9531 (0.22%)	
occurrences causally related to treatment / all	1 / 26	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast mass			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical dysplasia			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			

subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial atrophy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genital haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gynaecomastia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic fibrosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic haemorrhage			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic obstruction			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatism			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	7 / 9562 (0.07%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	2 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine fibrosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			

subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	6 / 9562 (0.06%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 1	
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute respiratory failure			
subjects affected / exposed	11 / 9562 (0.12%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 12	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 2	
Aspiration			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Asthma			
subjects affected / exposed	14 / 9562 (0.15%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	1 / 18	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthmatic crisis			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial obstruction			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choking			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	27 / 9562 (0.28%)	41 / 9531 (0.43%)	
occurrences causally related to treatment / all	0 / 41	3 / 57	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic respiratory failure			

subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diaphragmatic paralysis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	35 / 9562 (0.37%)	29 / 9531 (0.30%)	
occurrences causally related to treatment / all	9 / 36	4 / 29	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dyspnoea exertional			
subjects affected / exposed	5 / 9562 (0.05%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 5	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottic cyst			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	20 / 9562 (0.21%)	11 / 9531 (0.12%)	
occurrences causally related to treatment / all	16 / 20	9 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	2 / 4	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrothorax			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic interstitial pneumonia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Interstitial lung disease			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Laryngeal oedema			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal haemorrhage			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organising pneumonia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthopnoea			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranasal cyst			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	1 / 9562 (0.01%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	16 / 9562 (0.17%)	19 / 9531 (0.20%)	
occurrences causally related to treatment / all	0 / 16	1 / 19	
deaths causally related to treatment / all	0 / 3	0 / 1	
Pulmonary fibrosis			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	10 / 9562 (0.10%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary sarcoidosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary toxicity			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory alkalosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory disorder			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	8 / 9562 (0.08%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 2	0 / 2	
Restrictive pulmonary disease			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus congestion			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	4 / 9562 (0.04%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Adjustment disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Affective disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Borderline personality disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Confusional state			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium tremens			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	6 / 9562 (0.06%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression suicidal			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disorientation			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Illness anxiety disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropsychiatric symptoms			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device dislocation			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device loosening			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Device occlusion			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile output decreased			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood follicle stimulating hormone increased			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose fluctuation			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	5 / 9562 (0.05%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood lactic acid increased			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urine present			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram abnormal			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glycosylated haemoglobin increased			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate irregular			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Occult blood positive			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen saturation decreased			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic specific antigen increased			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			

subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count decreased			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment depression			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B surface antigen positive			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accident at home			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Adrenal gland injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic leak			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic stenosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	8 / 9562 (0.08%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 8	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropod bite			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Avulsion fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns third degree			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbon monoxide poisoning			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery restenosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract traumatic			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			

subjects affected / exposed	7 / 9562 (0.07%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary vascular graft occlusion			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary vascular graft stenosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Dislocation of sternum			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epidural haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural haematoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extraskkeletal ossification			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to anastomose			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	8 / 9562 (0.08%)	15 / 9531 (0.16%)	
occurrences causally related to treatment / all	0 / 8	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in gastrointestinal tract			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	8 / 9562 (0.08%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Heat stroke			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	8 / 9562 (0.08%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			

subjects affected / exposed	12 / 9562 (0.13%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 12	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyphaema			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	12 / 9562 (0.13%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 13	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbosacral plexus injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Median nerve injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	9 / 9562 (0.09%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle injury			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nail injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root injury lumbar			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			

subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprocedural myocardial infarction			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Post procedural complication			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural fever			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	4 / 9562 (0.04%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	11 / 9562 (0.12%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	6 / 11	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative respiratory failure			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thoracic procedure complication			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 2	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary contusion			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation pneumonitis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	6 / 9562 (0.06%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	4 / 9562 (0.04%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt malfunction			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skeletal injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin abrasion			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	2 / 9562 (0.02%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	0 / 9562 (0.00%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury cervical			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomal hernia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	23 / 9562 (0.24%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	12 / 23	3 / 6	
deaths causally related to treatment / all	0 / 2	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	8 / 9562 (0.08%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	3 / 8	3 / 5	
deaths causally related to treatment / all	0 / 0	2 / 2	
Tendon injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	2 / 9562 (0.02%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	3 / 9562 (0.03%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			
subjects affected / exposed	7 / 9562 (0.07%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	4 / 7	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Traumatic haemothorax			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			

subjects affected / exposed	11 / 9562 (0.12%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	4 / 11	1 / 7	
deaths causally related to treatment / all	1 / 2	0 / 0	
Ulna fracture			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	6 / 9562 (0.06%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention postoperative			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft complication			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Corneal dystrophy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glucose-6-phosphate dehydrogenase deficiency			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurofibromatosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	20 / 9562 (0.21%)	22 / 9531 (0.23%)	
occurrences causally related to treatment / all	3 / 20	1 / 22	
deaths causally related to treatment / all	0 / 1	0 / 2	

Acute left ventricular failure subjects affected / exposed	5 / 9562 (0.05%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute myocardial infarction subjects affected / exposed	126 / 9562 (1.32%)	197 / 9531 (2.07%)	
occurrences causally related to treatment / all	6 / 133	7 / 203	
deaths causally related to treatment / all	0 / 14	0 / 19	
Angina pectoris subjects affected / exposed	200 / 9562 (2.09%)	251 / 9531 (2.63%)	
occurrences causally related to treatment / all	5 / 239	7 / 267	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable subjects affected / exposed	354 / 9562 (3.70%)	405 / 9531 (4.25%)	
occurrences causally related to treatment / all	13 / 403	16 / 449	
deaths causally related to treatment / all	0 / 0	1 / 1	
Aortic valve disease subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis subjects affected / exposed	8 / 9562 (0.08%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	0 / 8	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arteriosclerosis coronary artery			

subjects affected / exposed	9 / 9562 (0.09%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 1	
Atrial fibrillation			
subjects affected / exposed	82 / 9562 (0.86%)	76 / 9531 (0.80%)	
occurrences causally related to treatment / all	0 / 84	3 / 80	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	12 / 9562 (0.13%)	13 / 9531 (0.14%)	
occurrences causally related to treatment / all	0 / 13	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	16 / 9562 (0.17%)	18 / 9531 (0.19%)	
occurrences causally related to treatment / all	3 / 16	2 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			

subjects affected / exposed	12 / 9562 (0.13%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	1 / 12	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bifascicular block			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	15 / 9562 (0.16%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	2 / 15	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	7 / 9562 (0.07%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	1 / 7	1 / 12	
deaths causally related to treatment / all	1 / 6	1 / 9	
Cardiac disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			

subjects affected / exposed	64 / 9562 (0.67%)	87 / 9531 (0.91%)	
occurrences causally related to treatment / all	2 / 84	0 / 108	
deaths causally related to treatment / all	0 / 11	0 / 9	
Cardiac failure acute			
subjects affected / exposed	20 / 9562 (0.21%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	6 / 27	0 / 15	
deaths causally related to treatment / all	0 / 4	0 / 4	
Cardiac failure chronic			
subjects affected / exposed	18 / 9562 (0.19%)	30 / 9531 (0.31%)	
occurrences causally related to treatment / all	0 / 19	1 / 44	
deaths causally related to treatment / all	0 / 1	1 / 2	
Cardiac failure congestive			
subjects affected / exposed	60 / 9562 (0.63%)	47 / 9531 (0.49%)	
occurrences causally related to treatment / all	0 / 71	2 / 53	
deaths causally related to treatment / all	0 / 4	0 / 3	
Cardiac tamponade			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac valve disease			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ventricular scarring			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 2	
Cardiogenic shock			

subjects affected / exposed	6 / 9562 (0.06%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 4	0 / 4	
Cardiomyopathy			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery disease			
subjects affected / exposed	85 / 9562 (0.89%)	90 / 9531 (0.94%)	
occurrences causally related to treatment / all	3 / 89	5 / 95	
deaths causally related to treatment / all	0 / 0	0 / 2	
Coronary artery insufficiency			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Coronary artery occlusion			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	14 / 9562 (0.15%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 14	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dressler's syndrome			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	7 / 9562 (0.07%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Microvascular coronary artery disease			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve stenosis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial fibrosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial infarction			
subjects affected / exposed	41 / 9562 (0.43%)	65 / 9531 (0.68%)	
occurrences causally related to treatment / all	0 / 43	1 / 66	
deaths causally related to treatment / all	0 / 11	0 / 16	
Myocardial ischaemia			
subjects affected / exposed	36 / 9562 (0.38%)	47 / 9531 (0.49%)	
occurrences causally related to treatment / all	1 / 37	0 / 50	
deaths causally related to treatment / all	0 / 0	0 / 2	
Myocarditis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal arrhythmia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial haemorrhage			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis constrictive			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prinzmetal angina			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary valve incompetence			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinoatrial block			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrhythmia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			

subjects affected / exposed	7 / 9562 (0.07%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	5 / 9562 (0.05%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular extrasystoles			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	5 / 9562 (0.05%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	1 / 5	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 9562 (0.01%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			

subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular asystole			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	4 / 9562 (0.04%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 4	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	10 / 9562 (0.10%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	1 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adams-Stokes syndrome			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amnesia			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia infarction			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain hypoxia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brain injury			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem haemorrhage			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	2 / 3	0 / 0	
Brain stem infarction			

subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	18 / 9562 (0.19%)	21 / 9531 (0.22%)	
occurrences causally related to treatment / all	0 / 18	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid sinus syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cauda equina syndrome			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar stroke			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral arteriosclerosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral atrophy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	6 / 9562 (0.06%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	3 / 6	3 / 6	
deaths causally related to treatment / all	1 / 2	2 / 4	
Cerebral infarction			

subjects affected / exposed	18 / 9562 (0.19%)	27 / 9531 (0.28%)	
occurrences causally related to treatment / all	2 / 19	2 / 28	
deaths causally related to treatment / all	0 / 2	0 / 3	
Cerebral ischaemia			
subjects affected / exposed	7 / 9562 (0.07%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral small vessel ischaemic disease			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	3 / 9562 (0.03%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 3	1 / 9	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cerebrovascular insufficiency			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical cord compression			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical radiculopathy			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cluster headache			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Dementia			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic coma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	9 / 9562 (0.09%)	13 / 9531 (0.14%)	
occurrences causally related to treatment / all	0 / 10	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	14 / 9562 (0.15%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	1 / 15	2 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic cerebral infarction			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Embololic stroke			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Encephalopathy			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 9562 (0.01%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 2	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Epileptic encephalopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential tremor			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	1 / 9562 (0.01%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Focal dyscognitive seizures			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 9562 (0.01%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 1	2 / 4	
deaths causally related to treatment / all	1 / 1	0 / 1	
Haemorrhagic stroke			
subjects affected / exposed	10 / 9562 (0.10%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	7 / 10	6 / 9	
deaths causally related to treatment / all	3 / 3	1 / 2	
Haemorrhagic transformation stroke			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianopia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			

subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	5 / 9562 (0.05%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic encephalopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic seizure			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial pressure increased			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	85 / 9562 (0.89%)	119 / 9531 (1.25%)	
occurrences causally related to treatment / all	1 / 88	0 / 127	
deaths causally related to treatment / all	0 / 8	0 / 5	
Lacunar infarction			
subjects affected / exposed	9 / 9562 (0.09%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar stroke			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	4 / 9562 (0.04%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 4	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			

subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microsleep			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paralysis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	1 / 9562 (0.01%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinsonism			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral nerve lesion			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic headache			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			

subjects affected / exposed	5 / 9562 (0.05%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudoradicular syndrome			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Putamen haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	4 / 9562 (0.04%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sedation			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	2 / 9562 (0.02%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal epidural haematoma			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 2	3 / 3	
deaths causally related to treatment / all	0 / 0	1 / 1	
Syncope			
subjects affected / exposed	26 / 9562 (0.27%)	27 / 9531 (0.28%)	
occurrences causally related to treatment / all	0 / 29	1 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamic infarction			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamus haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic outlet syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	39 / 9562 (0.41%)	33 / 9531 (0.35%)	
occurrences causally related to treatment / all	3 / 39	1 / 34	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular encephalopathy			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery dissection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery stenosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			

subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia with Lewy bodies			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Miller Fisher syndrome			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paralysis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paresis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Abdominal lymphadenopathy			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agranulocytosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	20 / 9562 (0.21%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	13 / 20	3 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia macrocytic			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of chronic disease			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of malignant disease			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deficiency anaemia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			

subjects affected / exposed	10 / 9562 (0.10%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	7 / 10	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenic purpura			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Increased tendency to bruise			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	26 / 9562 (0.27%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	13 / 26	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrogenic anaemia			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spontaneous haematoma			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	3 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spontaneous haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia vitamin B12 deficiency			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness neurosensory			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness unilateral			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear pain			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eustachian tube dysfunction			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoacusis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inner ear disorder			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniere's disease			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane perforation			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanosclerosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	13 / 9562 (0.14%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 13	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	7 / 9562 (0.07%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			

subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Age-related macular degeneration			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphakia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	22 / 9562 (0.23%)	30 / 9531 (0.31%)	
occurrences causally related to treatment / all	0 / 26	1 / 35	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract cortical			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract diabetic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal degeneration			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			

subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Entropion			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	4 / 9562 (0.04%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	3 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacrimal disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular pseudohole			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Maculopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open angle glaucoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal degeneration			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			

subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	2 / 2	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy proliferative			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhegmatogenous retinal detachment			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strabismus			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trichiasis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	9 / 9562 (0.09%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	5 / 9	2 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous opacities			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			

subjects affected / exposed	7 / 9562 (0.07%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	1 / 9562 (0.01%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal inflammation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis noninfective			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendix disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bezoar			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Change of bowel habit			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastrointestinal bleeding			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coeliac disease			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Constipation			
subjects affected / exposed	4 / 9562 (0.04%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental caries			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gastroparesis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diaphragmatic hernia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	18 / 9562 (0.19%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	1 / 18	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diverticulitis oesophageal			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	4 / 9562 (0.04%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 4	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	5 / 9562 (0.05%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	4 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal polyp			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	4 / 9562 (0.04%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	2 / 4	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	7 / 9562 (0.07%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	7 / 8	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	2 / 9562 (0.02%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epigastric discomfort			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faeces discoloured			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric antral vascular ectasia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	6 / 9562 (0.06%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	5 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	5 / 9562 (0.05%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	18 / 9562 (0.19%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	8 / 18	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			

subjects affected / exposed	6 / 9562 (0.06%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	2 / 6	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	8 / 9562 (0.08%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	2 / 8	2 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	9 / 9562 (0.09%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	4 / 9	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	6 / 9562 (0.06%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	3 / 6	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenal ulcer			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			

subjects affected / exposed	43 / 9562 (0.45%)	22 / 9531 (0.23%)	
occurrences causally related to treatment / all	30 / 44	18 / 23	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ischaemia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stenosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer haemorrhage			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	2 / 3	2 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	5 / 9562 (0.05%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 6	2 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	3 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	5 / 9562 (0.05%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 5	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernial eventration			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	4 / 9562 (0.04%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Incarcerated inguinal hernia			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	16 / 9562 (0.17%)	20 / 9531 (0.21%)	
occurrences causally related to treatment / all	0 / 16	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	6 / 9562 (0.06%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	4 / 6	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Intestinal obstruction			
subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal pseudo-obstruction			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal strangulation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	18 / 9562 (0.19%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	1 / 18	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	3 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar hernia			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			

subjects affected / exposed	12 / 9562 (0.13%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	5 / 12	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstruction gastric			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal motility disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal spasm			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer haemorrhage			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis ulcerative			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic mass			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic pseudocyst			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	11 / 9562 (0.12%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 14	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 1	
Pancreatitis acute			
subjects affected / exposed	2 / 9562 (0.02%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatolithiasis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontal disease			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal adhesions			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	13 / 9562 (0.14%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	11 / 13	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux gastritis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland calculus			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	3 / 9562 (0.03%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swollen tongue			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth disorder			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth socket haemorrhage			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative gastritis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	4 / 9562 (0.04%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia, obstructive			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	22 / 9562 (0.23%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	17 / 23	7 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss syndrome			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			

subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bile duct stone			
subjects affected / exposed	7 / 9562 (0.07%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyskinesia			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 9562 (0.01%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholangitis acute			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis chronic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			

subjects affected / exposed	13 / 9562 (0.14%)	23 / 9531 (0.24%)	
occurrences causally related to treatment / all	0 / 14	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	19 / 9562 (0.20%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	0 / 19	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	5 / 9562 (0.05%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholelithiasis			
subjects affected / exposed	23 / 9562 (0.24%)	25 / 9531 (0.26%)	
occurrences causally related to treatment / all	0 / 24	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Drug-induced liver injury			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder disorder			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	4 / 9562 (0.04%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic failure			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Steatohepatitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic elastosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angioedema			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	29 / 9562 (0.30%)	18 / 9531 (0.19%)	
occurrences causally related to treatment / all	0 / 32	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ulcer			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ecchymosis			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intertrigo			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic skin ulcer			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen planus			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myxoid cyst			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrobiosis lipoidica diabetorum			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petechiae			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prurigo			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin exfoliation			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin mass			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	7 / 9562 (0.07%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	0 / 7	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	3 / 9562 (0.03%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Henoch-Schonlein purpura			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	56 / 9562 (0.59%)	39 / 9531 (0.41%)	
occurrences causally related to treatment / all	2 / 59	2 / 43	
deaths causally related to treatment / all	0 / 1	0 / 1	
Azotaemia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck obstruction			

subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck sclerosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder tamponade			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	3 / 9562 (0.03%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urethral			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	6 / 9562 (0.06%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	9 / 9562 (0.09%)	15 / 9531 (0.16%)	
occurrences causally related to treatment / all	0 / 10	0 / 15	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystitis haemorrhagic			

subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	6 / 9562 (0.06%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysuria			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	4 / 9562 (0.04%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Glomerulonephritis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulosclerosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	32 / 9562 (0.33%)	13 / 9531 (0.14%)	
occurrences causally related to treatment / all	16 / 33	8 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage urinary tract			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	4 / 9562 (0.04%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Micturition disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephritic syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	16 / 9562 (0.17%)	21 / 9531 (0.22%)	
occurrences causally related to treatment / all	1 / 19	1 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvi-ureteric obstruction			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephritis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery arteriosclerosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery occlusion			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			

subjects affected / exposed	16 / 9562 (0.17%)	15 / 9531 (0.16%)	
occurrences causally related to treatment / all	2 / 17	2 / 15	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal hypertension			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	10 / 9562 (0.10%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 10	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal injury			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	18 / 9562 (0.19%)	13 / 9531 (0.14%)	
occurrences causally related to treatment / all	1 / 20	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral haemorrhage			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	5 / 9562 (0.05%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder polyp			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	4 / 9562 (0.04%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	5 / 9562 (0.05%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism primary			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis subacute			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	5 / 9562 (0.05%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			

subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	10 / 9562 (0.10%)	14 / 9531 (0.15%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	0 / 9562 (0.00%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest wall mass			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondromalacia			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compartment syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crystal arthropathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic amyotrophy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial asymmetry			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	1 / 4	2 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty tophus			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal mass			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	16 / 9562 (0.17%)	19 / 9531 (0.20%)	
occurrences causally related to treatment / all	0 / 17	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc space narrowing			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint contracture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint swelling			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loose body in joint			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	13 / 9562 (0.14%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 13	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscal degeneration			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			

subjects affected / exposed	9 / 9562 (0.09%)	15 / 9531 (0.16%)	
occurrences causally related to treatment / all	0 / 9	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	2 / 9562 (0.02%)	9 / 9531 (0.09%)	
occurrences causally related to treatment / all	0 / 2	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myofascitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			

subjects affected / exposed	47 / 9562 (0.49%)	55 / 9531 (0.58%)	
occurrences causally related to treatment / all	1 / 51	1 / 57	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteopenia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteorrhagia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	4 / 9562 (0.04%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patellofemoral pain syndrome			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	6 / 9562 (0.06%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			

subjects affected / exposed	5 / 9562 (0.05%)	8 / 9531 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sacroiliitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scoliosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seronegative arthritis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sjogren's syndrome			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	8 / 9562 (0.08%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal ligament ossification			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			

subjects affected / exposed	6 / 9562 (0.06%)	11 / 9531 (0.12%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon disorder			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis stenosans			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess jaw			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess neck			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acinetobacter infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute endocarditis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute sinusitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			

subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	13 / 9562 (0.14%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	0 / 14	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial diarrhoea			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cellulitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	18 / 9562 (0.19%)	22 / 9531 (0.23%)	
occurrences causally related to treatment / all	0 / 18	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	35 / 9562 (0.37%)	45 / 9531 (0.47%)	
occurrences causally related to treatment / all	0 / 40	0 / 51	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis gangrenous			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis of male external genital organ			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis infective			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			

subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complicated appendicitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	4 / 9562 (0.04%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryocystitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue haemorrhagic fever			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Device related infection			

subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	11 / 9562 (0.12%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	1 / 12	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysentery			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysematous cystitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	0 / 9562 (0.00%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 0	1 / 5	
deaths causally related to treatment / all	0 / 0	1 / 2	
Endophthalmitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis infectious			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterobacter pneumonia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	4 / 9562 (0.04%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottitis			

subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	12 / 9562 (0.13%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	0 / 12	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 9562 (0.02%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye infection viral			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	5 / 9562 (0.05%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	0 / 5	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	14 / 9562 (0.15%)	18 / 9531 (0.19%)	
occurrences causally related to treatment / all	1 / 15	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	0 / 9562 (0.00%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genitourinary tract infection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter gastritis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes ophthalmic			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes virus infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	5 / 9562 (0.05%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected bite			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected cyst			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected dermal cyst			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious colitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of bronchiectasis			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Influenza			
subjects affected / exposed	8 / 9562 (0.08%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Joint abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labyrinthitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	7 / 9562 (0.07%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ludwig angina			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	10 / 9562 (0.10%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 12	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Meningitis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Meningococcal infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	5 / 9562 (0.05%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			

subjects affected / exposed	14 / 9562 (0.15%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 16	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	3 / 9562 (0.03%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media acute			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media chronic			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreas infection			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papilloma viral infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotitis			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal abscess			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital cellulitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	3 / 9562 (0.03%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal abscess			

subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	130 / 9562 (1.36%)	147 / 9531 (1.54%)	
occurrences causally related to treatment / all	1 / 137	4 / 153	
deaths causally related to treatment / all	0 / 9	0 / 10	
Pneumonia bacterial			
subjects affected / exposed	3 / 9562 (0.03%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia escherichia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia streptococcal			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	2 / 9562 (0.02%)	3 / 9531 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural sepsis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	3 / 9562 (0.03%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	8 / 9562 (0.08%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pyelonephritis acute			

subjects affected / exposed	3 / 9562 (0.03%)	12 / 9531 (0.13%)	
occurrences causally related to treatment / all	0 / 3	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	4 / 9562 (0.04%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonellosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	14 / 9562 (0.15%)	20 / 9531 (0.21%)	
occurrences causally related to treatment / all	0 / 15	0 / 20	
deaths causally related to treatment / all	0 / 4	0 / 5	
Septic shock			

subjects affected / exposed	7 / 9562 (0.07%)	7 / 9531 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 3	0 / 2	
Sinusitis			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal infection			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			
subjects affected / exposed	4 / 9562 (0.04%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			

subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis mycoplasmal			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis of genitourinary system			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	3 / 9562 (0.03%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteritis			

subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	33 / 9562 (0.35%)	36 / 9531 (0.38%)	
occurrences causally related to treatment / all	2 / 37	1 / 50	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	12 / 9562 (0.13%)	10 / 9531 (0.10%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 3	
Vestibular neuronitis			
subjects affected / exposed	1 / 9562 (0.01%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	2 / 9562 (0.02%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval abscess			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cellulitis			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			

subjects affected / exposed	5 / 9562 (0.05%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis B			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis C			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis C			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis Escherichia coli			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
West Nile viral infection			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	6 / 9562 (0.06%)	5 / 9531 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	24 / 9562 (0.25%)	42 / 9531 (0.44%)	
occurrences causally related to treatment / all	0 / 28	0 / 46	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	50 / 9562 (0.52%)	60 / 9531 (0.63%)	
occurrences causally related to treatment / all	0 / 55	0 / 78	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic complication			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	10 / 9562 (0.10%)	11 / 9531 (0.12%)	
occurrences causally related to treatment / all	0 / 11	0 / 13	
deaths causally related to treatment / all	0 / 2	0 / 0	
Diabetic metabolic decompensation			
subjects affected / exposed	9 / 9562 (0.09%)	17 / 9531 (0.18%)	
occurrences causally related to treatment / all	0 / 9	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Euglycaemic diabetic ketoacidosis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	5 / 9562 (0.05%)	6 / 9531 (0.06%)	
occurrences causally related to treatment / all	1 / 7	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	20 / 9562 (0.21%)	22 / 9531 (0.23%)	
occurrences causally related to treatment / all	0 / 21	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	5 / 9562 (0.05%)	4 / 9531 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertriglyceridaemia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			

subjects affected / exposed	33 / 9562 (0.35%)	25 / 9531 (0.26%)	
occurrences causally related to treatment / all	0 / 39	0 / 26	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypokalaemia			
subjects affected / exposed	2 / 9562 (0.02%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 9562 (0.01%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	5 / 9562 (0.05%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophosphataemia			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	0 / 9562 (0.00%)	2 / 9531 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	2 / 9562 (0.02%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metabolic acidosis			

subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	1 / 9562 (0.01%)	0 / 9531 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	12 / 9562 (0.13%)	19 / 9531 (0.20%)	
occurrences causally related to treatment / all	0 / 12	1 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin D deficiency			
subjects affected / exposed	0 / 9562 (0.00%)	1 / 9531 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Ticagrelor	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1951 / 9562 (20.40%)	610 / 9531 (6.40%)	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1951 / 9562 (20.40%)	610 / 9531 (6.40%)	
occurrences (all)	2479	687	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 May 2015	Ticagrelor dose changed from 90 mg bd to 60 mg bd. Changes in secondary objectives From: The secondary objectives of the study (presented in hierarchical order) are to compare the effect of long-term treatment with ticagrelor versus placebo for 1 Prevention of the composite of all-cause death, MI or stroke. 2 Prevention of CV death. 3 Prevention of all-cause death. To: The secondary objectives of the study (presented in hierarchical order) are to compare the effect of long-term treatment with ticagrelor versus placebo for 1 Prevention of CV death. 2 Prevention of MI. 3 Prevention of ischaemic stroke. 4 Prevention of all-cause death.
23 September 2015	An increase in number of patients to be enrolled in the study, and a change in the anticipated length of the study
07 February 2017	A change in the anticipated length of the study to increase the number of primary endpoint events collected. Inclusion of collection of concomitant medications at study closure visit.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Overall 19271 patients were randomised to study drug, of which 51 patients were randomised to study drug at a site prematurely closed by sponsor and these patients were excluded from the study results.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/30788847>

<http://www.ncbi.nlm.nih.gov/pubmed/31475798>

<http://www.ncbi.nlm.nih.gov/pubmed/31484629>